» Articles » PMID: 33692468

Nuclear βArrestin1 Regulates Androgen Receptor Function in Castration Resistant Prostate Cancer

Overview
Journal Oncogene
Date 2021 Mar 11
PMID 33692468
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Progression of prostate cancer (PC) to terminal castration-resistant PC (CRPC) involves a diverse set of intermediates, and androgen receptor (AR) is the key mediator of PC initiation and progression to CRPC. Hence, identification of factors involved in the regulation of AR expression and function is a necessary first-step to improve disease outcome. In this study, we identified ubiquitous βArrestin 1 (βArr1) as a regulator of AR function in CRPC. Unbiased gene expression analysis of public datasets revealed increased levels of ARRB1 (the gene encoding βArr1) in CRPC when compared to normal tissue. Further, βArr1 expression correlated with enhanced AR transcriptional function in these datasets. The βArr1 partitions to both nucleus and cytosol and mechanistic studies showed that nuclear, and not cytosolic, βArr1 formed a complex with AR and AR-coregulator βCatenin and that the heterotrimeric protein complex was recruited to androgen-response elements of AR-regulated genes. Functionally, we demonstrate that depletion of βArr1 attenuates PC cell and tumor growth and metastasis, and rescued expression of nuclear, but not cytosolic, βArr1 restores the PC colony growth and invasion of Matrigel in vitro and tumor growth and metastasis in mice. The targeting of βArr1-regulated AR transcriptional function may be used in the development of new drugs to treat lethal CRPC.

Citing Articles

-Arrestins: Structure, Function, Physiology, and Pharmacological Perspectives.

Wess J, Oteng A, Rivera-Gonzalez O, Gurevich E, Gurevich V Pharmacol Rev. 2023; 75(5):854-884.

PMID: 37028945 PMC: 10441628. DOI: 10.1124/pharmrev.121.000302.


Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer.

Mao Y, Yang G, Li Y, Liang G, Xu W, Hu M Cancers (Basel). 2022; 14(15).

PMID: 35954408 PMC: 9367587. DOI: 10.3390/cancers14153744.

References
1.
Claessens F, Helsen C, Prekovic S, Van den Broeck T, Spans L, van Poppel H . Emerging mechanisms of enzalutamide resistance in prostate cancer. Nat Rev Urol. 2014; 11(12):712-6. DOI: 10.1038/nrurol.2014.243. View

2.
Watson P, Arora V, Sawyers C . Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015; 15(12):701-11. PMC: 4771416. DOI: 10.1038/nrc4016. View

3.
Dehm S, Tindall D . Alternatively spliced androgen receptor variants. Endocr Relat Cancer. 2011; 18(5):R183-96. PMC: 3235645. DOI: 10.1530/ERC-11-0141. View

4.
Titus M, Schell M, Lih F, Tomer K, Mohler J . Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005; 11(13):4653-7. DOI: 10.1158/1078-0432.CCR-05-0525. View

5.
Heemers H, Tindall D . Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007; 28(7):778-808. DOI: 10.1210/er.2007-0019. View